Cognitive screening in HTLV-1-infected people using a self-perceived memory score and auditory P300.


Journal

Journal of neurovirology
ISSN: 1538-2443
Titre abrégé: J Neurovirol
Pays: United States
ID NLM: 9508123

Informations de publication

Date de publication:
02 2022
Historique:
received: 12 07 2021
accepted: 09 12 2021
revised: 21 11 2021
pubmed: 16 2 2022
medline: 11 5 2022
entrez: 15 2 2022
Statut: ppublish

Résumé

The HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is the most common neurological manifestation associated with human T-cell lymphotropic virus type-1 (HTLV-1) infection. Although cognitive impairment has been highlighted in the spectrum of HTLV-1 neurological manifestations, it may go unnoticed in those who do not spontaneously report it. We aimed at evaluating the applicability of a self-perceived memory score (SMS) and the cognitive event-related potential (P300) for early detection of cognitive impairment in HTLV-1-infected people. The SMS was measured by a 0-10 point numeric scale combined with a sad-happy face rating scale. The higher the number, the better was the SMS. The P300 was obtained through an oddball paradigm with a mental counting task. The participants were 15 (21.4%) individuals with HAM/TSP, 20 (28.6%) HTLV-1 asymptomatic carriers, and 35 (50%) seronegative controls. We found that SMS (p < 0.001) and P300 latency (p < 0.001) got progressively worse from the seronegative controls to the asymptomatic carriers and then to the HAM/TSP. The results that indicated cognitive impairment were SMS < 7.2 points and P300 latency > 369.0 ms. The HAM/TSP group showed the highest prevalence of altered P300 (80%) and SMS (87%). Interestingly, the asymptomatic group also presented significantly higher prevalence of altered SMS (60%) and P300 (35%) when compared to controls (< 10%). The frequency of cognitive impairment was 16 times higher in the HTLV-1 asymptomatic group and 69 times higher in the HAM/TSP group when compared to controls. The use of SMS in the medical consultation was a useful and easy-to-apply method to screen HTLV-1-infected subjects for everyday memory complaints.

Identifiants

pubmed: 35167053
doi: 10.1007/s13365-021-01044-1
pii: 10.1007/s13365-021-01044-1
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

123-132

Informations de copyright

© 2022. Journal of NeuroVirology, Inc.

Références

Aji BM, Larner AJ (2017) Screening for dementia: single yes/no question or Likert scale? Clin Med 17:93–94
doi: 10.7861/clinmedicine.17-1-93
Allain J-P, Stramer SL, Carneiro-Proietti ABF, Martins ML, da Silva SNL, Ribeiro M et al (2009) Transfusion-transmitted infectious diseases. Biologicals 37:71–77
pubmed: 19231236 doi: 10.1016/j.biologicals.2009.01.002
Almeida OP, Almeida SA (1999) Reliability of the Brazilian version of the geriatric depression scale (GDS) short form. Arq Neuropsiquiatr 57:421–426
pubmed: 10450349 doi: 10.1590/S0004-282X1999000300013
American Encephalographic Society (1994) Guideline thirteen: guidelines for standard electrode position nomenclature. J Clin Neurophysiol 11:111–113
doi: 10.1097/00004691-199401000-00014
Andrade RG, Ribeiro MA, Namen-Lopes MSS, Silva SMN, Basques FV, Ribas JG et al (2010) Evaluation of the use of real-time PCR for human T cell lymphotropic virus 1 and 2 as a confirmatory test in screening for blood donors. Rev Soc Bras Med Trop 43:111–115
pubmed: 20464136 doi: 10.1590/S0037-86822010000200001
Araujo AQ, Silva MTT (2006) The HTLV-1 neurological complex. Lancet Neurol 5:1068–1076
pubmed: 17110288 doi: 10.1016/S1474-4422(06)70628-7
Baddeley A (2003) Working memory: looking back and looking forward. Nat Rev Neurosci 4:829–839
pubmed: 14523382 doi: 10.1038/nrn1201
Bennys K, Portet F, Touchon J, Rondouin G (2007) Diagnostic value of event-related evoked potentials N200 and P300 subcomponents in early diagnosis of Alzheimer’s disease and mild cognitive impairment. J Clin Neurophysiol 24:405–412
pubmed: 17912065 doi: 10.1097/WNP.0b013e31815068d5
Bidelman GM, Lowther JE, Tak SH, Alain C (2017) Mild cognitive impairment is characterized by deficient brainstem and cortical representations of speech. J Neurosci 37:3610–3620
pubmed: 28270574 pmcid: 6596919 doi: 10.1523/JNEUROSCI.3700-16.2017
Caporali JFDM, Labanca L, Florentino KR, Souza BO, Gonçalves DU (2018) Intrarater and interrater agreement and reliability of vestibular evoked myogenic potential triggered by galvanic vestibular stimulation (galvanic-VEMP) for HTLV-1 associated myelopathy testing. PLoS One 13:e0204449
pubmed: 30261002 pmcid: 6160040 doi: 10.1371/journal.pone.0204449
Carneiro-Proietti ABF, Ribas JGR, Catalan-Soares BC, Martins ML, Brito-Melo GEA, Martins-Filho OA et al (2002) Infecção e doença pelos vírus linfotrópicos humanos de células T (HTLV-I/II) no Brasil. Rev Soc Bras Med Trop 35:499–508
pubmed: 12621671 doi: 10.1590/S0037-86822002000500013
Castelo MS, Coelho-Filho JM, Carvalho AF, Lima JWO, Noleto JCS, Ribeiro KG et al (2010) Validity of the Brazilian version of the Geriatric Depression Scale (GDS) among primary care patients. Int Psychogeriatrics 22:119–123
doi: 10.1017/S1041610209991219
Castro-Costa CMDE, Araújo AQC, Barreto MM, Takayanagui OM, Sohler MP, Silva ELMDA et al (2006) Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I- associated myelopathy (HAM/TSP). AIDS Res Hum Retroviruses 22:931–935
pubmed: 17067261 doi: 10.1089/aid.2006.22.931
Champs APS, de Azeredo Passos VM, Carvalho G, Barreto SM, Meirelles C, Caramelli P (2019) Cognitive impairment in HTLV-1-associated myelopathy, proviral load and inflammatory markers. Int J Infect Dis 84:121–126
pubmed: 31085316 doi: 10.1016/j.ijid.2019.05.010
Champs APS, Passos VMDA, Barreto SM, Caramelli P, de Melo CM, Carvalho G et al (2013) Encephalomyelopathy associated with HTLV-I: a primary disease or coexisting with multiple sclerosis? Dement Neuropsychol. 7:439–443
pubmed: 29213871 pmcid: 5619508 doi: 10.1590/S1980-57642013DN74000014
de Castro ARR, Labanca L, de Resende LM, Utsch-Gonçalves D (2020) Case report: Cognitive impairment without clinical spinal disease may be the first sign of HTLV-1 neurological alteration. Am J Trop Med Hyg 102:366–369
pubmed: 31833466 pmcid: 7008323 doi: 10.4269/ajtmh.19-0218
de Morais Caporali JF, Gonçalves DU, Labanca L, de Oliveira LD, de Melo Trindade GV, de Almeida PT et al (2016) Vestibular evoked myogenic potential (VEMP) triggered by galvanic vestibular stimulation (GVS): a promising tool to assess spinal cord function in schistosomal myeloradiculopathy. PLoS Negl Trop Dis 10:e0004672
doi: 10.1371/journal.pntd.0004672
Diniz JLCP, Tupinambas U, Labanca L, Barbara SM, Souza O, Gonçalves DU (2016) The cognitive impairment of elderly living with human immunodeficiency virus (HIV): a cross-sectional study about the role of viral neurotoxicity. J Neuroinfectious Dis 7:224
Donchin E, Coles MGH (1988) Is the P300 component a manifestation of context updating? Behav Brain Sci 11:357–374
doi: 10.1017/S0140525X00058027
dos Santos TS, Mancini PC, Sancio LP, Castro AR, Labanca L, de Resende LM (2015) Achados da avaliação comportamental e eletrofisiológica do processamento auditivo. Audiol - Commun Res 20:225–232
doi: 10.1590/2317-6431-2015-1589
Fath-Elbab HK, Ahmed E, Mansour DF, Soliman WT (2018) Event-related evoked potential versus clinical tests in assessment of subclinical cognitive impairment in chronic hepatitis C virus. Egypt J Neurol Psychiatry Neurosurg 54:35
doi: 10.1186/s41983-018-0034-y
Felipe L, Goncalves DU, Santos MAR, Proietti FA, Ribas JGR, Carneiro-Proietti AB et al (2008) Vestibular-evoked myogenic potential (VEMP) to evaluate cervical myelopathy in human T-cell lymphotropic virus type I infection. Spine 33:1180–1184
pubmed: 18469690 doi: 10.1097/BRS.0b013e31817152ed
Felipe L, Kingma H, Lambertucci JR, Carneiro-Proietti AB, Gonçalves DU (2013) Testing the vestibular evoked myogenic potential (VEMP) to identify subclinical neurological alterations in different phases of human T-lymphotropic virus type 1 infection. Spine J 13:397–401
pubmed: 23267739 doi: 10.1016/j.spinee.2012.11.015
Friedman D (2003) Cognition and aging: a highly selective overview of event-related potential (ERP) data. J Clin Exp Neuropsychol 25:702–720
pubmed: 12815507 doi: 10.1076/jcen.25.5.702.14578
Fukushima T, Ikeda T, Uyama E, Uchino M, Okabe H, Ando M (1994) Cognitive event-related potentials and brain magnetic resonance imaging in HTLV-1 associated myelopathy (HAM). J Neurol Sci 126:30–39
pubmed: 7836944 doi: 10.1016/0022-510X(94)90091-4
Gascón MR, Haziot ME, Assone T, Fonseca LAM, Smid J, de Oliveira ACP et al (2019) Memory impairment: an intermediate clinical syndrome symptom in HTLV-1-infected patients? Arq Neuropsiquiatr 77:429–435
pubmed: 31314846 doi: 10.1590/0004-282x20190062
Gascón MRP, Casseb J, Smid J, Vidal JE, Fonseca LAM, Paiva A et al (2017) Cognitive impairment is frequent among symptomatic carriers of human T-cell lymphotropic virus type 1 (HTLV-1), regardless of their clinical status. J Neurol Sci 377:185–189
pubmed: 28477692 doi: 10.1016/j.jns.2017.04.019
Gifford KA, Liu D, Damon SM, Chapman WG, Romano RR, Samuels LR et al (2015) Subjective memory complaint only relates to verbal episodic memory performance in mild cognitive impairment. J Alzheimer’s Dis 44:309–318
doi: 10.3233/JAD-140636
Gironell A, García-Sánchez C, Estévez-González A, Boltes A, Kulisevsky J (2005) Usefulness of P300 in subjective memory complaints: a prospective study. J Clin Neurophysiol 22:279–284
pubmed: 16093901 doi: 10.1097/01.WNP.0000173559.60113.AB
Goncalves LR, Barbosa LNF, Magalhaes PMR, Rocha-Filho PAS (2017) Characterization of cognitive performance and evaluation of quality of life among patients with HTLV-1. Clin Neurol Neurosurg 160:142–146
doi: 10.1016/j.clineuro.2017.07.008
Gorrall B, Curtis J, Little T, Panko P (2016) Innovations in measurement: visual analog scales and retrospective pretest self-report designs. Actual En Psicol 30:2–7
doi: 10.15517/ap.v30i120.22932
Jiang S, Qu C, Wang F, Liu Y, Qiao Z, Qiu X et al (2015) Using event-related potential P300 as an electrophysiological marker for differential diagnosis and to predict the progression of mild cognitive impairment: a meta-analysis. Neurol Sci 36:1005–1012
Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155–163
pubmed: 27330520 pmcid: 4913118 doi: 10.1016/j.jcm.2016.02.012
Labanca L, de Morais Caporali JF, da Silva Carvalho SA, Lambertucci JR, Carneiro Proietti ABDF, Claudio L et al (2018) Vestibular-evoked myogenic potential triggered by galvanic vestibular stimulation may reveal subclinical alterations in human T-cell lymphotropic virus type 1-associated myelopathy. PLoS One 13:e0200536
pubmed: 30001400 pmcid: 6042765 doi: 10.1371/journal.pone.0200536
Labanca L, Starling ALB, de Sousa-Pereira SR, Romanelli LCF, de Freitas Carneiro-Proietti AB, Carvalho LN et al (2015) Electrophysiological analysis shows dizziness as the first symptom in human T cell lymphotropic virus type-associated myelopathy/tropical spastic paraparesis. AIDS Res Hum Retroviruses 31:649–654
pubmed: 25760424 pmcid: 4458737 doi: 10.1089/aid.2014.0153
Larroy C (2002) Comparing visual-analog and numeric scales for assessing menstrual pain. Behav Med United States 27:179–181
doi: 10.1080/08964280209596043
López-Góngora M, Escartín A, Martínez-Horta S, Fernández-Bobadilla R, Querol L, Romero S et al (2015) Neurophysiological evidence of compensatory brain mechanisms in early-stage multiple sclerosis. PLoS One 10:e0136786
pubmed: 26322632 pmcid: 4555654 doi: 10.1371/journal.pone.0136786
Magnie MN, Bensa C, Laloux L, Bertogliati C, Faure S, Lebrun C (2007) Contribution of cognitive evoked potentials for detecting early cognitive disorders in multiple sclerosis. Rev Neurol (Paris) 163:1065–1074
doi: 10.1016/S0035-3787(07)74179-6
Martin F, Fedina A, Youshya S, Taylor GP (2010) A 15-year prospective longitudinal study of disease progression in patients with HTLV-1 associated myelopathy in the UK. J Neurol Neurosurg Psychiatry 81:1336–1340
pubmed: 20660921 doi: 10.1136/jnnp.2009.191239
McPherson DL (1996) Late potentials of the auditory system. Stein L (ed). Evoked Potentials Ser. San Diego: Singular Publishing Group, Inc
Mendes GB, Kalil RS, Rosadas C, de Freitas MRG, Puccioni-Sohler M (2014) Temporal lesions and widespread involvement of white matter associated with multi-organ inflammatory disease in human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Int J Infect Dis 25:1–3
pubmed: 24815740 doi: 10.1016/j.ijid.2014.03.1374
Nakagawa M, Izumo S, Ijichi S, Kubota H, Arimura K, Kawabata M et al (1995) HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1:50–61
pubmed: 9222342 doi: 10.3109/13550289509111010
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699
pubmed: 15817019 doi: 10.1111/j.1532-5415.2005.53221.x
Nobre V, Guedes AC, Proietti FA, Martins ML, Nassif G, Serufo JC et al (2007) Increased prevalence of human T cell lymphotropic virus type 1 in patients attending a Brazilian dermatology clinic. Intervirology 50:316–318
pubmed: 17622792 doi: 10.1159/000105445
Osame M (1990) Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In: Blattner W (ed) Hum retrovirol, HTLV. Raven Press, New York, pp 191–197
Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H et al (1987) Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells. Ann Neurol 21:117–122
pubmed: 2881513 doi: 10.1002/ana.410210203
Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A et al (1986) HTLV-I associated myelopathy, a new clinical entity. Lancet 1:1031–1032
pubmed: 2871307 doi: 10.1016/S0140-6736(86)91298-5
Parra MA, Ascencio LL, Urquina HF, Manes F, Ibáñez AM (2012) P300 and neuropsychological assessment in mild cognitive impairment and alzheimer dementia. Front Neurol 3:172
pubmed: 23227021 pmcid: 3514532 doi: 10.3389/fneur.2012.00172
Pavarini SCI, Brigola AG, Luchesi BM, Souza ÉN, Rossetti ES, Fraga FJ et al (2018) On the use of the P300 as a tool for cognitive processing assessment in healthy aging: a review. Dement Neuropsychol 12:1–11
pubmed: 29682227 pmcid: 5901243 doi: 10.1590/1980-57642018dn12-010001
Pearman A, Hertzog C, Gerstorf D (2014) Little evidence for links between memory complaints and memory performance in very old age: longitudinal analyses from the Berlin aging study. Psychol Aging 29:828–842
pubmed: 25089853 doi: 10.1037/a0037141
Pedroso RV, Fraga FJ, Pavarini SCI, Nascimento CMC, Ayán C, Cominetti MR (2021) A systematic review of altered P300 event-related potential in apolipoprotein E4 (APOE4) carriers. Clin EEG Neurosci 52:193–200
pubmed: 32945192 doi: 10.1177/1550059420959966
Picton TW (1992) The P300 wave of the human event-related potential. J Clin Neurophysiol 9:456–479
pubmed: 1464675 doi: 10.1097/00004691-199210000-00002
Polich J (2007) Updating P300: an integrative theory of P3a and P3b. Clin Neurophysiol 118:2128–2148
pubmed: 17573239 pmcid: 2715154 doi: 10.1016/j.clinph.2007.04.019
Preston CC, Colman AM (2000) Optimal number of response categories in rating scales: reliability, validity, discriminating power, and respondent preferences. Acta Psychol (amst) 104:1–15
doi: 10.1016/S0001-6918(99)00050-5
Purser JL, Fillenbaum GG, Wallace RB (2006) Memory complaint is not necessary for diagnosis of mild cognitive impairment and does not predict 10-year trajectories of functional disability, word recall, or short portable mental status questionnaire limitations. J Am Geriatr Soc 54:355–358
Riffenburgh RH (2006) Statistics in medicine, 2nd edn. Academic Press, Cambridge, MA
Roberts JL, Clare L, Woods RT (2009) Subjective memory complaints and awareness of memory functioning in mild cognitive impairment: a systematic review. Dement Geriatr Cogn Disord 28:95–109
pubmed: 19684399 doi: 10.1159/000234911
Romanelli LC, Caramelli P, Martins ML, Goncalves DU, Proietti FA, Ribas JG et al (2013) Incidence of human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in a long-term prospective cohort study of initially asymptomatic individuals in Brazil. AIDS Res Hum Retroviruses 29:1199–1202
pubmed: 23617363 doi: 10.1089/aid.2013.0086
Romanelli LCF, Miranda DM, Carneiro-Proietti ABF, Mamede M, Vasconcelos HMM, Martins ML et al (2018) Spinal cord hypometabolism associated with infection by human T-cell lymphotropic virus type 1(HTLV-1). PLoS Negl Trop Dis 12:e0006720
pubmed: 30148843 pmcid: 6128630 doi: 10.1371/journal.pntd.0006720
Saliasi E, Geerligs L, Lorist MM, Maurits NM (2013) The relationship between P3 amplitude and working memory performance differs in young and older adults. PLoS One 8:e63701
pubmed: 23667658 pmcid: 3646823 doi: 10.1371/journal.pone.0063701
Schütze M, Romanelli LCF, Rosa DV, Carneiro-Proietti ABF, Nicolato R, Romano-Silva MA et al (2017) Brain metabolism changes in patients infected with HTLV-1. Front Mol Neurosci 10:52
pubmed: 28293169 pmcid: 5329009 doi: 10.3389/fnmol.2017.00052
Silva MTT, Mattos P, Alfano A, Araújo AQC (2003) Neuropsychological assessment in HTLV-1 infection: a comparative study among TSP/HAM, asymptomatic carriers, and healthy controls. J Neurol Neurosurg Psychiatry 78:1085–1089
doi: 10.1136/jnnp.74.8.1085
Silva TR, Santos MAR, de Resende LM, Labanca L, Caporali JFDM, Dias RTS et al (2020) Vestibular evoked myogenic potential on ocular, cervical, and soleus muscles to assess the extent of neurological impairment in HTLV-1 infection. Front Neurol 11:433
pubmed: 32508741 pmcid: 7253674 doi: 10.3389/fneur.2020.00433
Starling ALB, Coelho-Dos-Reis JGA, Peruhype-Magalhães V, Pascoal-Xavier MA, Gonçalves DU, Béla SR et al (2015) Immunological signature of the different clinical stages of the HTLV-1 infection: establishing serum biomarkers for HTLV-1-associated disease morbidity. Biomarkers 20:502–512
pubmed: 26474234 doi: 10.3109/1354750X.2015.1094141
Studart AN, Nitrini R (2016) Subjective cognitive decline: the first clinical manifestation of Alzheimer’s disease? Dement Neuropsychol Brazil 10:170–177
doi: 10.1590/S1980-5764-2016DN1003002
Taherdoost H (2019) What is the best response scale for survey and questionnaire design; review of different lengths of rating scale / attitude scale / Likert scale. Int J Acad Res Manag 8:hal-02557308
Tales A, Jessen F, Butler C, Wilcock G, Phillips J, Bayer T (2015) Subjective cognitive decline. J Alzheimer’s Dis 48(Suppl 1):S1-3
Tanajura D, Castro N, Oliveira P, Neto A, Muniz A, Carvalho NB et al (2015) Neurological manifestations in human T-cell lymphotropic virus type 1 (HTLV-1)-infected individuals without HTLV-1-associated myelopathy/tropical spastic paraparesis: a longitudinal cohort study. Clin Infect Dis 61:49–56
pubmed: 25820277 pmcid: 4542911 doi: 10.1093/cid/civ229
Tokic K, Titlic M, Beganovic-Petrovic A, Suljic E, Romac R, Silic S (2016) P300 wave changes in patients with parkinson’s disease. Med Arch 70:453–456
pubmed: 28210020 pmcid: 5292223 doi: 10.5455/medarh.2016.70.453-456
Torrens-Burton A, Basoudan N, Bayer AJ, Tales A (2017) Perception and reality of cognitive function: information processing speed, perceived memory function, and perceived task difficulty in older adults. J Alzheimers Dis 60:1601–1609
pubmed: 28984584 pmcid: 5676981 doi: 10.3233/JAD-170599
van Harten AC, Mielke MM, Swenson-Dravis DM, Hagen CE, Edwards KK, Roberts RO et al (2018) Subjective cognitive decline and risk of MCI: the Mayo Clinic study of aging. Neurology United States 91:e300–e312
doi: 10.1212/WNL.0000000000005863
World Health Organization (1991) WHO report of the informal working group on prevention of deafness and hearing impairment programme planning. Geneva. Available from: https://apps.who.int/iris/handle/10665/58839 . Accessed 02 July 2021
Zorzi G, Mancuso R, Nardocci N, Farina L, Guerini FR, Ferrante P (2010) Childhood-onset HAM/TSP with progressive cognitive impairment. Neurol Sci 31:209–212
pubmed: 20076981 doi: 10.1007/s10072-009-0204-x

Auteurs

Aline Rejane Rosa de Castro (ARR)

Graduate Program of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.

Ludimila Labanca (L)

Graduate Program of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Graduate Program of Speech, Language, and Hearing Sciences, Faculty of Medicine, Universidade Federal de Minas Gerais, Av. Professor Alfredo Balena, 190, sala 199, Belo Horizonte, Minas Gerais, CEP 30110130, Brazil.

Luciana Macedo de Resende (LM)

Graduate Program of Speech, Language, and Hearing Sciences, Faculty of Medicine, Universidade Federal de Minas Gerais, Av. Professor Alfredo Balena, 190, sala 199, Belo Horizonte, Minas Gerais, CEP 30110130, Brazil.

Marjore Rhaissa de Sousa (MR)

Graduate Program of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.

Rafael Teixeira Scoralick Dias (RTS)

Graduate Program of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.

Júlia Fonseca de Morais Caporali (JF)

Graduate Program of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.

Denise Utsch-Gonçalves (D)

Graduate Program of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. deniseg@medicina.ufmg.br.
Graduate Program of Speech, Language, and Hearing Sciences, Faculty of Medicine, Universidade Federal de Minas Gerais, Av. Professor Alfredo Balena, 190, sala 199, Belo Horizonte, Minas Gerais, CEP 30110130, Brazil. deniseg@medicina.ufmg.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH